Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review

被引：0
|
作者：
Tandiono, J. [1 ]
Chen, S. [1 ]
Marcella, E. [1 ]
Susanto, B. [1 ]
Heriyanto, R. S. [1 ]
Wijovi, F. [1 ]
Tancherla, A. [1 ]
Kurniawan, A. [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Tangerang, Indonesia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
114P
引用
收藏
页码：S759 / S760
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [2] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Qiao Liu
    Lidan Yi
    Xia Luo
    Sini Li
    Liting Wang
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    [J]. Advances in Therapy, 2021, 38 : 3962 - 3972
  • [3] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    [J]. ADVANCES IN THERAPY, 2021, 38 (07) : 3962 - 3972
  • [4] First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review
    Goffin, John
    Lacchetti, Christina
    Ellis, Peter M.
    Ung, Yee C.
    Evans, William K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) : 260 - 274
  • [5] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the United States
    Berling, M.
    Chaudhary, M. A.
    Yuan, Y.
    Varol, N.
    Dale, P.
    Testa, E.
    Klint, J.
    Lee, A.
    Lubinga, S. J.
    Penrod, J. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S16
  • [7] A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
    Cuc Thi Thu Nguyen
    Petrelli, Fabio
    Scuri, Stefania
    Binh Thanh Nguyen
    Grappasonni, Iolanda
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (05): : 763 - 777
  • [8] A SYSTEMATIC REVIEW OF PHARMACOECONOMIC EVALUATION OF ERLOTINIB IN THE FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Nguyen, T. T.
    Grappasonni, I
    Nguyen, T. B.
    Petrelli, F.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A438 - A438
  • [9] A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
    Cuc Thi Thu Nguyen
    Fabio Petrelli
    Stefania Scuri
    Binh Thanh Nguyen
    Iolanda Grappasonni
    [J]. The European Journal of Health Economics, 2019, 20 : 763 - 777
  • [10] First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study
    Imai, Hisao
    Kijima, Takashi
    Azuma, Koichi
    Kishi, Kazuma
    Saito, Haruhiro
    Yamaguchi, Teppei
    Tanizaki, Junko
    Yoneshima, Yasuto
    Fujita, Kohei
    Watanabe, Satoshi
    Kitazono, Satoru
    Fukuhara, Tatsuro
    Hataji, Osamu
    Toi, Yukihiro
    Mizutani, Hideaki
    Hamakawa, Yusuke
    Maemondo, Makoto
    Ohsugi, Tomoyuki
    Suzuki, Keisuke
    Horinouchi, Hidehito
    Ohe, Yuichiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (04) : 452 - 462
12345